🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Report Clinical Lung Cancer shows potential benefit of using ctDNA in pts with advanced squamous NSCLC. In 131pts at 13 institutions (N America, France, Spain), relevant results in 26% of pts. ESCAT tier 1 alterations in 4% including #EGFR, #ALK, #BRAF, #MET. clinical-lung-cancer.com/article/S1525-…

Reminder of the impact of social determinants of health in young patients with lung cancer Clinical Lung Cancer. Query of National Cancer Database shows Black patients under age 50 are more likely to present with stage 4 disease and more likely to be uninsured. clinical-lung-cancer.com/article/S1525-…

Real world completion rates for chemoradiation in stage III NSCLC Clinical Lung Cancer. 246/265 pts (93%) who started CRT completed it. Reasons pts did not complete: toxicity, other illness, progression. Durvalumab here associated with improved OS (HR 0.39). clinical-lung-cancer.com/article/S1525-…

A review on maintenance therapy for #SCLC with Dr. Luis Paz-Ares now Clinical Lung Cancer outlining the rationale, prior efforts, and future prospects for adding therapy after induction chemotherapy but before progression. clinical-lung-cancer.com/article/S1525-…

Explore a new study on recurrence patterns and risk factors in early-stage resected lung adenocarcinoma with common EGFR mutations. A multicenter retrospective cohort study from South Korea. Full study: bit.ly/3RbHDbk

New case series alert: #Tepotinib combined with EGFR tyrosine kinase inhibitor therapy in patients with EGFR-mutant, MET-altered NSCLC bit.ly/4iQwAA2 Xiuning Le MD PhD

Phase II clinical trial of #atezolizumab in patients with advanced thymic carcinoma: ORR 14.7%, DCR 58.8%, mPFS 3.2 months, and 24-mo OS 63.2%. Better outcomes observed in PD-L1+ vs. PD-L1- patients (ORR: 40.0% vs. 0%; PFS: 7.4 vs. 1.5 months). bit.ly/425HnRo

🔥 Clinical Lung Cancer 🆙 ✅Real-World Outcomes of Tarlatamab in SCLC 🎯Special considerations are required for pts with brain mets due to the increased risk of severe #ICANS 👥 Dr. Fabian J. Bolte #LCSM OncoAlert clinical-lung-cancer.com/article/S1525-…

🔥 Clinical Lung Cancer 🆙 ✅ctDNA can detect minimal residual disease in curative treated NSCLC patients using a tumor agnostic approach 🎯The timing of blood sampling is crucial for the prognostic value of ctDNA 👥 Dr. Lærke Rosenlund #LCSM OncoAlert lungcancerjournal.info/article/S0169-…

Happy to share our study on advanced lung carcinoids w/ actionable genomic alterations (AGA) authors.elsevier.com/c/1kx275QwJC0L… 🔶2.5% of🫁carcinoids that underwent NGS w/ Caris Life Sciences had AGAs (1.2% w/ commercially available targeted tx) 🔶Genotype-matched targeted tx were a/w clinical benefit

Goutham Sunny Dr SAURABH SONI Dr. Foxpaws Fauxpas Journal of Clinical Oncology Vanita Noronha, MBBS MD DM Minit Shah Nandini Menon CORE Diagnostics Dr Amol Akhade Ashish Singh Tata Memorial Hospital bhawna sirohi Sujith Amol Patel Ajoy Oommen John Another clinically relevant Indian study of mutational landscape in young patients with lung cancer where oncogene fusions are more common Clinical Lung Cancer sciencedirect.com/science/articl…

Immune checkpoint inhibitors have reshaped treatment for early-stage NSCLC. Read the latest article on this paradigm shift. "Immunotherapy for Early-Stage NSCLC: A Practical Guide of Current Controversies" 🔗 bit.ly/44xeE9V

Explore a new retrospective study of patients with multiple sclerosis diagnosed with lung cancer, analyzing clinical, molecular, and survival data. Full article: bit.ly/3Zddo8i

A new retrospective study suggests that EGFR exon 19 non-LRE deletions may be linked to poorer outcomes with #osimertinib, and rare exon 19 mutations (e.g., L747P, P753L) exhibit variable responses. Full article: bit.ly/4kpT8IX

Brigatinib post crizotinib in #ALK NSCLC Clinical Lung Cancer from LudaBazhenovaMD. High response rates seen independent of secondary ALK mutations but if alterations seen in non-ALK secondary drivers (EGFR, KRAS, BRAF, MET0, no responses seen. clinical-lung-cancer.com/article/S1525-…

📢🔥NEW in @ClinLungCancer: Can chemo + anti–PD-(L)1 improve outcomes in PD-L1–negative squamous NSCLC? Our team conducted a meta-analysis of 11 phase III RCTs (n=1548) — the largest to date! 📄 doi.org/10.1016/j.cllc… Led by stellar IM resident @peruzzo_nc 👏 🧵Thread:

Real world outcomes in Japan with 1L osimertinib monotherapy in #EGFR NSCLC (OSI-FACT-OS) Clinical Lung Cancer. With median f/u of 37m, mPFS 20.1m and mOS 42m. All grade pneumonitis rate 16.7% (G3+ was 5.2%), uncommon after first year on therapy. clinical-lung-cancer.com/article/S1525-…

Genomic landscape of resected invasive mucinous adenocarcinoma Clinical Lung Cancer (n=107). KRAS mutations common - in 70.1% of cases - with NRG1 fusions identified in 9.2% of cases. Best identified with RNA seq. clinical-lung-cancer.com/article/S1525-…

Outcomes Following 1L Immune Checkpoint Inhibitors +/- Chemo Stratified by KRAS Mutational Status -- Real-World Analysis in Pts w/ Advanced NSCLC [May 28, 2025] Cantor et al Charu Aggarwal, MD, MPH, FASCO Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-… #lcsm #ImmunoOnc #PrecisionMedicine Tempus

3y f/u from Italian Phase IIIB MAURIS trial Clinical Lung Cancer - 1L carboplatin + etoposide + atezolizumab in a broader, real-world population. 1y OS rate 45.5%, 2y OS rate 31.0%, 3y OS rate 14.5%, mOS 10.6m, mPFS 5.5m. clinical-lung-cancer.com/article/S1525-…